8-K current report · filed Oct 13, 2026

Bausch & Lomb Corp (BLCO) 8-K Current Report: October 13, 2026

Item 5.02Item 7.01Item EX-99.1BLCO overview

Short answer

Bausch & Lomb Corp (BLCO) filed an 8-K current report with the SEC on October 13, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). CEO Brent Saunders departed October 12, 2026, also leaving the board, with no reported dispute or disagreement.

Bausch & Lomb Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 5.02 · Departure/Election of Directors or Officers

  • CEO Brent Saunders departed October 12, 2026, also leaving the board, with no reported dispute or disagreement
  • Chairman Thomas J. Appio appointed interim CEO while continuing as Bausch Health CEO, increasing parent-company influence
  • Separation payment totals $75.5 million, plus up to $50,000 in reimbursed attorneys’ fees
  • Saunders forfeited and cancelled all outstanding equity awards, including vested and unvested incentives
  • Transition support for 90 days, with two years of continued health-plan eligibility and existing restrictive covenants retained

Item 7.01 · Regulation FD Disclosure

  • CEO Saunders’ departure and Mr. Appio’s appointment as interim CEO, signaling an immediate leadership transition
  • Expected 2026 adjusted EBITDA guidance increase, excluding Acquired IPR&D, indicating improved outlook for underlying profitability
  • Exhibit 99.1 contains the company’s press release with transition details and updated guidance context

Item EX-99.1 · Exhibit EX-99.1

  • Thomas J. Appio appointed interim CEO immediately while retaining Bausch Health CEO role
  • Brent Saunders departing by mutual agreement, creating leadership transition risk for BLCO
  • Appio’s prior Bausch + Lomb leadership experience may support continuity and strategy execution
  • Preliminary third-quarter performance supports expected increase to full-year 2026 adjusted EBITDA excluding Acquired IPR&D guidance
  • Revised guidance details and third-quarter results scheduled for October 28, 2026, subject to unaudited close procedures

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Bausch & Lomb Corp 8-K filings

Get the next BLCO 8-K as it lands

Follow BLCO for push alerts, or ask the research agent what this filing means.